Literature DB >> 1589804

The management of intractable bone pain: a clinician's perspective.

J A Campa1, R Payne.   

Abstract

Bone metastases occur in up to 85% of patients (at autopsy) who have breast, lung, and prostate cancer, and are a common cause of pain and neurological morbidity in patients with these and other cancers. The management of pain, the most common complication of bone metastasis, requires a knowledge of specific clinical syndromes and the associated neurological and orthopedic morbidities, as well as an understanding of current antitumor and pharmacological therapies. Knowledge of these potential complications are important in the design of clinical trials that seek to evaluate the effectiveness of new treatments for bone metastasis. Although radiation therapy in combination with analgesic drug therapies remains the mainstay of treatment, much recent interest in drugs with specific effects on bone elements, especially the osteoclast, offer the promise of providing effective pain relief with fewer side effects than is currently possible with conventional therapies.

Entities:  

Mesh:

Year:  1992        PMID: 1589804     DOI: 10.1016/s0001-2998(05)80151-5

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  10 in total

1.  Neurophysiology of Cancer Pain: From the Laboratory to the Clinic.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

Review 2.  The pathophysiology and management of spine metastasis from lung cancer.

Authors:  J S Greenberger
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 3.  Strategies for management of prostate cancer-related bone pain.

Authors:  R C Pelger; V Soerdjbalie-Maikoe; N A Hamdy
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Strontium 89 in the treatment of pain due to diffuse osseous metastases: a university hospital experience.

Authors:  Ebrahim Ashayeri; Adedamola Omogbehin; Rajagopalan Sridhar; Ravi A Shankar
Journal:  J Natl Med Assoc       Date:  2002-08       Impact factor: 1.798

5.  Production, quality control and pharmacokinetic studies of Ho-EDTMP for therapeutic applications.

Authors:  Ali Bahrami-Samani; Reza Bagheri; Amir R Jalilian; Simindokht Shirvani-Arani; Mohammad Ghannadi-Maragheh; Mojtaba Shamsaee
Journal:  Sci Pharm       Date:  2010-06-09

6.  Re-HEDP : pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose.

Authors:  Eduardo Savio; Javier Gaudiano; Ana M Robles; Henia Balter; Andrea Paolino; Andrea López; Juan C Hermida; Eugenia De Marco; Graciela Martinez; Eduardo Osinaga; Furn F Knapp
Journal:  BMC Nucl Med       Date:  2001

7.  Production, Quality Control and Biological Evaluation of (166)Ho-PDTMP as a Possible Bone Palliation Agent.

Authors:  Samaneh Zolghadri; Amir Reza Jalilian; Zohreh Naseri; Hassan Yousefnia; Ali Bahrami-Samani; Mohammad Ghannadi-Maragheh; Hossein Afarideh
Journal:  Iran J Basic Med Sci       Date:  2013-05       Impact factor: 2.699

8.  Production and quality control 177Lu (NCA)-DOTMP as a potential agent for bone pain palliation.

Authors:  Nafise Salek; Mojtaba Shamsaei; Mohammad Ghannadi Maragheh; Simindokht Shirvani Arani; Ali Bahrami Samani
Journal:  J Appl Clin Med Phys       Date:  2016-11-08       Impact factor: 2.102

9.  Production, Quality Control and Pharmacokinetic Studies of (177)Lu-EDTMP for Human Bone Pain Palliation Therapy Trials.

Authors:  Ali Bahrami-Samani; Akbar Anvari; Amir Reza Jalilian; Simindokht Shirvani-Arani; Hassan Yousefnia; Mahmoud Reza Aghamiri; Mohammad Ghannadi-Maragheh
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

10.  Development of (166)Holmium-1,2 Propylene Di-amino Tetra (Methy1enephosphonicacid) as a Possible Bone Palliation Agent.

Authors:  Samaneh Zolghadri; Amir Reza Jalilian; Hassan Yousefnia; Ali Bahrami-Samani; Mohammad Ghannadi-Maragheh
Journal:  World J Nucl Med       Date:  2014-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.